Regional ileitis. A pathological and clinical entity, By Burril B. Crohn, vol.251, issue.1, pp.73-79, 1932. ,
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease, New England Journal of Medicine, vol.348, issue.7, pp.348601-608, 2003. ,
DOI : 10.1056/NEJMoa020888
Natural History of Pediatric Crohn's Disease: A Population-Based Cohort Study, Gastroenterology, vol.135, issue.4, pp.1106-1113, 2008. ,
DOI : 10.1053/j.gastro.2008.06.079
I am Jewish, Inflammatory Bowel Diseases, vol.72, issue.Supplement, pp.26-27, 2008. ,
DOI : 10.1086/367848
Geographical variations of inflammatory bowel disease in France: A study based on national health insurance data, Inflammatory Bowel Diseases, vol.12, issue.3, pp.218-226, 2006. ,
DOI : 10.1053/gast.2003.50021
URL : https://hal.archives-ouvertes.fr/hal-00466309
The changing pattern of Crohn's disease incidence in northern France: a continuing increase in the 10-to 19-year-old age bracket, Aliment Pharmacol Ther, issue.10, pp.331133-1142, 1988. ,
Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: evidence from health administrative data, Gut, vol.58, issue.11, pp.581490-1497, 2009. ,
DOI : 10.1136/gut.2009.188383
Crohn's disease severity in familial and sporadic cases, Gut, vol.44, issue.1, pp.91-95, 1999. ,
DOI : 10.1136/gut.44.1.91
IBD: a family affair, Best Practice & Research Clinical Gastroenterology, vol.18, issue.3, pp.525-539, 2004. ,
DOI : 10.1016/j.bpg.2003.12.006
Family and twin studies in inflammatory bowel disease. World journal of gastroenterology : WJG, pp.3668-3672, 2006. ,
Role of ATG16L, NOD2 and IL23R in Crohn's disease pathogenesis, World journal of gastroenterology : WJG, vol.2012, issue.185, pp.412-424 ,
The Genetics of Inflammatory Bowel Disease, The American Journal of Gastroenterology, vol.11, issue.12, pp.2820-2831, 2007. ,
DOI : 10.1111/j.1365-2036.2005.02635.x
Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease, Nature Genetics, vol.164, issue.10, pp.401211-1215, 2008. ,
DOI : 10.1038/nature06010
URL : http://europepmc.org/articles/pmc2770437?pdf=render
NOD2 mutations predict the risk for surgery in pediatric-onset Crohn's disease, Journal of Pediatric Surgery, vol.45, issue.8, pp.451591-1597, 2010. ,
DOI : 10.1016/j.jpedsurg.2009.10.046
New genes in inflammatory bowel disease: lessons for complex diseases?, The Lancet, vol.367, issue.9518, pp.1271-1284, 2006. ,
DOI : 10.1016/S0140-6736(06)68345-1
Tobacco and IBD: relevance in the understanding of disease mechanisms and clinical practice, Best Practice & Research Clinical Gastroenterology, vol.18, issue.3, pp.481-496, 2004. ,
DOI : 10.1016/j.bpg.2003.12.003
Active and Passive Smoking in Childhood Is Related to the Development of Inflammatory Bowel Disease, Inflammatory Bowel Diseases, vol.13, issue.4, pp.431-438, 2007. ,
DOI : 10.1093/ije/13.2.235
Imbalances in Dietary Consumption of Fatty Acids, Vegetables, and Fruits Are Associated With Risk for Crohn's Disease in Children, The American Journal of Gastroenterology, vol.12, issue.170, pp.2016-2025, 2007. ,
DOI : 10.1136/gut.2004.054353
[Environmental risk factors in Crohn's disease and ulcerative colitis (excluding tobacco and appendicectomy)], Gastroenterol Clin Biol, vol.30, pp.6-7859, 2006. ,
Diversity of the Human Intestinal Microbial Flora, Science, vol.308, issue.5728, pp.1635-1638, 2005. ,
DOI : 10.1126/science.1110591
Microbiota in Pediatric Inflammatory Bowel Disease, The Journal of Pediatrics, vol.157, issue.2, pp.240-244, 2010. ,
DOI : 10.1016/j.jpeds.2010.02.046
Low counts of Faecalibacterium prausnitzii in colitis microbiota, Inflammatory Bowel Diseases, vol.40, issue.8, pp.1183-1189, 2009. ,
DOI : 10.1128/JCM.40.12.4423-4427.2002
URL : https://hal.archives-ouvertes.fr/hal-00657435
Presenting features of inflammatory bowel disease in Great Britain and Ireland, Archives of Disease in Childhood, vol.88, issue.11, pp.995-1000, 2003. ,
DOI : 10.1136/adc.88.11.995
Nutritional Status and Growth in Pediatric Crohn's Disease: A Population-Based Study, The American Journal of Gastroenterology, vol.105, issue.8, pp.1051893-1900, 2010. ,
DOI : 10.1002/ibd.20069
Pediatric modification of the Montreal classification for inflammatory bowel disease, Inflammatory Bowel Diseases, vol.31, issue.6suppl, pp.1314-1321, 2011. ,
DOI : 10.1016/S1054-139X(02)00485-8
Correlation of C-Reactive Protein With Clinical, Endoscopic, Histologic, and Radiographic Activity in Inflammatory Bowel Disease, Inflammatory Bowel Diseases, vol.128, issue.8, pp.11707-712, 2005. ,
DOI : 10.1097/01.CRD.0000077906.74217.6E
Diagnostic value of serological assays in pediatric inflammatory bowel disorders. Digestion Oussalah A, Gueant JL, Peyrin-Biroulet L: Meta-analysis: hyperhomocysteinaemia in inflammatory bowel diseases, Aliment Pharmacol Ther, vol.75, issue.2910, pp.210-214, 2007. ,
Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, pp.40547-553, 2008. ,
Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study, Gut, issue.7, pp.30983-989, 1989. ,
Usefulness of wireless capsule endoscopy in paediatric inflammatory bowel disease. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, pp.43220-224, 2011. ,
Small bowel video capsule endoscopy in Crohn's disease: What have we learned in the last ten years? World journal of gastrointestinal endoscopy, pp.23-29, 2011. ,
Natural history of Crohn??s disease, Inflammatory Bowel Diseases, vol.34, issue.6, pp.953-961, 2010. ,
DOI : 10.1136/gut.34.7.939
A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY, The Lancet, vol.315, issue.8167, p.514, 1980. ,
DOI : 10.1016/S0140-6736(80)92767-1
Development and validation of a pediatric Crohn's disease activity index, J Pediatr Gastroenterol Nutr, vol.12, issue.4, pp.439-447, 1991. ,
Incidence of stricturing and penetrating complications of Crohn??s disease diagnosed in pediatric patients, Inflammatory Bowel Diseases, vol.97, issue.4, pp.638-644, 2010. ,
DOI : 10.1111/j.1572-0241.2002.05915.x
Risk Factors Associated With Progression to Intestinal Complications of Crohn's Disease in a Population-Based Cohort, Gastroenterology, vol.139, issue.4, pp.1147-1155, 2010. ,
DOI : 10.1053/j.gastro.2010.06.070
Defective IL10 Signaling Defining a Subgroup of Patients With Inflammatory Bowel Disease, The American Journal of Gastroenterology, vol.29, issue.8, pp.1544-1555, 2011. ,
DOI : 10.1016/j.immuni.2008.11.003
Inflammatory Bowel Disease and Mutations Affecting the Interleukin-10 Receptor, New England Journal of Medicine, vol.361, issue.21, pp.3612033-2045, 2009. ,
DOI : 10.1056/NEJMoa0907206
Infliximab therapy in children with Crohn???s disease: a one-year evaluation of efficacy comparing ???top-down??? and ???step-up??? strategies, Acta Paediatrica, vol.48, issue.Suppl 2 ,
DOI : 10.1080/10428190701345433
Meta-analysis: enteral nutrition in active Crohn???s disease in children, Alimentary Pharmacology & Therapeutics, vol.24, issue.Suppl. 1, pp.795-806, 2007. ,
DOI : 10.1016/0016-5085(88)90230-2
Enteral nutritional therapy for induction of remission in Crohn's disease, Cochrane Database Syst Rev, vol.2007, issue.1, p.542 ,
Review article: diet and inflammatory bowel disease - epidemiology and treatment, Alimentary Pharmacology & Therapeutics, vol.126, issue.Suppl. 10, pp.99-112, 2009. ,
DOI : 10.1080/00365520510023729
Prevention of relapse by mesalazine (Pentasa??) in pediatric Crohn's disease: A multicenter, double-blind, randomized, placebo-controlled trial, Gastroent??rologie Clinique et Biologique, vol.33, issue.1, pp.31-40, 2009. ,
DOI : 10.1016/j.gcb.2008.07.007
Budesonide versus prednisolone for the treatment of active Crohn's disease in children, European Journal of Gastroenterology & Hepatology, vol.16, issue.1, pp.47-54, 2004. ,
DOI : 10.1097/00042737-200401000-00008
Tolerance and efficacy of azathioprine in pediatric Crohn's disease, Inflamm Bowel Dis, issue.10, pp.172138-2143, 2011. ,
Evaluating the use of metabolite measurement in children receiving treatment with a thiopurine, Alimentary Pharmacology & Therapeutics, vol.374, issue.Suppl. 1, pp.1106-1114, 2011. ,
DOI : 10.1016/S0140-6736(09)61302-7
Association of 6-Thioguanine Nucleotide Levels and Inflammatory Bowel Disease Activity: A Meta-Analysis, Gastroenterology, vol.130, issue.4, pp.1047-1053, 2006. ,
DOI : 10.1053/j.gastro.2006.01.046
Methotrexate Following Unsuccessful Thiopurine Therapy in Pediatric Crohn's Disease, The American Journal of Gastroenterology, vol.17, issue.2, pp.2804-2812, 2007. ,
DOI : 10.1136/gut.48.5.591
Thalidomide Use and Outcomes in Pediatric Patients With Crohn Disease Refractory to Infliximab and Adalimumab, Journal of Pediatric Gastroenterology and Nutrition, vol.54, issue.1, pp.28-33 ,
DOI : 10.1097/MPG.0b013e318228349e
Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in Pediatric Crohn???s Disease, The American Journal of Gastroenterology, vol.132, issue.12, pp.3042-3049, 2009. ,
DOI : 10.1097/MPG.0b013e3181957a11
Maintenance Therapy with Certolizumab Pegol for Crohn's Disease, New England Journal of Medicine, vol.357, issue.3, pp.239-250, 2007. ,
DOI : 10.1056/NEJMoa062897
Natalizumab Therapy for Moderate to Severe Crohn Disease in Adolescents, Journal of Pediatric Gastroenterology and Nutrition, vol.44, issue.2, pp.185-191, 2007. ,
DOI : 10.1097/01.mpg.0000252191.05170.e7
Review article: medical therapy for fistulizing Crohn's disease, Alimentary Pharmacology and Therapeutics, vol.17, issue.48 ,
DOI : 10.1111/j.1572-0241.1999.00848.x
New therapies for inflammatory bowel disease: from the bench to the bedside, Gut, vol.61, issue.6, pp.918-932 ,
DOI : 10.1136/gutjnl-2011-300904
Clinical Pharmacokinetics and Use??of??Infliximab, Clinical Pharmacokinetics, vol.20, issue.1, pp.645-660, 2007. ,
DOI : 10.3748/wjg.v11.i8.1187
Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials, Clinical Therapeutics, vol.33, issue.7, pp.33946-964, 2011. ,
DOI : 10.1016/j.clinthera.2011.06.002
Transmembrane TNFalpha: structure, function and interaction with anti-TNF agents, Rheumatology (Oxford), vol.2010, issue.497, pp.1215-1228 ,
DOI : 10.1093/rheumatology/keq031
URL : https://academic.oup.com/rheumatology/article-pdf/49/7/1215/5049610/keq031.pdf
Infliximab Therapy in Children and Adolescents with Inflammatory Bowel Disease, Drugs, vol.40, issue.12, pp.1703-1723, 2007. ,
DOI : 10.1053/gast.2003.50182
Infliximab Therapy in Children With Concurrent Perianal Crohn Disease: Observations From REACH, Journal of Pediatric Gastroenterology and Nutrition, vol.49, issue.2 ,
DOI : 10.1097/MPG.0b013e3181a70f21
Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials, Clinical Gastroenterology and Hepatology, vol.6, issue.6, pp.644-653, 2008. ,
DOI : 10.1016/j.cgh.2008.03.014
Premedication and Infusion Reactions With Infliximab: Results From a Pediatric Inflammatory Bowel Disease Consortium, Inflammatory Bowel Diseases, vol.33, issue.5, pp.442-446, 2005. ,
DOI : 10.1046/j.1365-2036.2003.01411.x
Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease ,
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn???s disease, Gastroenterology, vol.126, issue.2, pp.402-413, 2004. ,
DOI : 10.1053/j.gastro.2003.11.014
Induction and Maintenance Infliximab Therapy for the Treatment of Moderate-to-Severe Crohn???s Disease in Children, Gastroenterology, vol.132, issue.3, pp.863-873, 2007. ,
DOI : 10.1053/j.gastro.2006.12.003
Efficacy of Infliximab in Pediatric Crohn??s Disease: A Randomized Multicenter Open-Label Trial Comparing Scheduled to On Demand Maintenance Therapy, Inflammatory Bowel Diseases, vol.134, issue.3, pp.388-394, 2009. ,
DOI : 10.1053/j.gastro.2008.03.004
Resolution of Severe Peristomal Pyoderma Gangrenosum With Infliximab in a Child With Crohn Disease, Journal of Pediatric Gastroenterology and Nutrition, vol.34, issue.5, pp.558-560, 2002. ,
DOI : 10.1097/00005176-200205000-00016
Dermatologic Manifestations of Crohn Disease in Children: Response to Infliximab, Journal of Pediatric Gastroenterology and Nutrition, vol.37, issue.2, pp.150-154, 2003. ,
DOI : 10.1097/00005176-200308000-00013
Retrospective Case Review of Pediatric Patients with Uveitis Treated with Infliximab, Ophthalmology, vol.113, issue.2, pp.308-314, 2006. ,
DOI : 10.1016/j.ophtha.2005.09.037
Association of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn???s Disease, Clinical Gastroenterology and Hepatology, vol.4, issue.10, pp.1248-1254, 2006. ,
DOI : 10.1016/j.cgh.2006.06.025
Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF, Inflamm Bowel Dis, issue.11, pp.161898-1904, 2010. ,
Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis Inflammatory bowel disease in children and adolescents: recommendations for diagnosis--the Porto criteria, Gut J Pediatr Gastroenterol Nutr, vol.59, issue.741, pp.49-54, 2005. ,
Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach, Biometrics, vol.44, issue.3, pp.837-845, 1988. ,
DOI : 10.2307/2531595
Crohn??s Jejunoileitis: The Pediatrician??s Perspective on Diagnosis and Management, Inflammatory Bowel Diseases, vol.39, issue.7, pp.696-704, 2005. ,
DOI : 10.1007/BF02055108
Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease, Inflamm Bowel Dis, issue.10, pp.141392-1398, 2008. ,
Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn's Disease, Clinical Gastroenterology and Hepatology, vol.9, issue.5, pp.421-427 ,
DOI : 10.1016/j.cgh.2011.02.008
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial, The Lancet, vol.366, issue.9494, pp.3661367-1374, 2005. ,
DOI : 10.1016/S0140-6736(05)67566-6
Association of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn???s Disease, Clinical Gastroenterology and Hepatology, vol.4, issue.10, pp.1248-1254, 2006. ,
DOI : 10.1016/j.cgh.2006.06.025
The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebocontrolled trial, Arthritis Rheum, issue.6, pp.461451-1459, 2002. ,
Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn's disease, Inflamm Bowel Dis, vol.2012, issue.8, pp.181480-1487 ,
Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease, Clinical Immunology, vol.118, issue.1, pp.11-19, 2006. ,
DOI : 10.1016/j.clim.2005.07.010
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease, New England Journal of Medicine, vol.362, issue.15, pp.1383-1395253, 2007. ,
DOI : 10.1056/NEJMoa0904492
Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease, Clinical Gastroenterology and Hepatology, vol.2, issue.5, pp.410-417, 2004. ,
DOI : 10.1016/S1542-3565(04)00127-2
Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease, The American Journal of Gastroenterology, vol.26, issue.5, pp.1133-1139, 2010. ,
DOI : 10.1053/j.gastro.2006.11.041
Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel Disease, Inflammatory Bowel Diseases, vol.16, issue.7, pp.181199-1206 ,
DOI : 10.1002/ibd.21259
High infliximab trough levels are associated with mucosal healing in Crohn's disease. Program and abstracts of Digestive Disease Week (DDW) 2010, 2010. ,
P0721 FECAL CALPROTECTIN AS A MARKER OF INTESTINAL INFLAMMATION IN CHILDREN WITH IBD, THROUGH EVOLUTIONARY STAGES AND UNDER TREATMENT., Journal of Pediatric Gastroenterology and Nutrition, vol.39, issue.Supplement 1, p.331, 2004. ,
DOI : 10.1097/00005176-200406001-00845